BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19262076)

  • 1. [Evaluation of the MicroScan NegCombo panel Type 44 for detection of extended-spectrum beta-lactamase among clinical isolates of Escherichia coli, Klebsiella species, and Proteus mirabilis].
    Ko SY; Chung JW; Song AJ; Yoon NS; Sung H; Kim MN
    Korean J Lab Med; 2009 Feb; 29(1):35-40. PubMed ID: 19262076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the Phoenix automated microbiology system for detecting extended-spectrum beta-lactamase in Escherichia coli, Klebsiella species and Proteus mirabilis].
    Lee KK; Kim ST; Hong KS; Huh HJ; Chae SL
    Korean J Lab Med; 2008 Jun; 28(3):185-90. PubMed ID: 18594169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
    Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
    J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital.
    Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH
    APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
    Moland ES; Sanders CC; Thomson KS
    J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC beta-lactamases and extended-spectrum beta-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis.
    Song W; Jeong SH; Kim JS; Kim HS; Shin DH; Roh KH; Lee KM
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):315-8. PubMed ID: 17174510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristic of fluoroquinolone resistant clinical isolates of K. pneumoniae, P. mirabilis and E. coli producing ESBL and AmpC beta-lactamases].
    Rzeczkowska M; Piekarska K; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(4):285-95. PubMed ID: 23484420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.
    Wiegand I; Geiss HK; Mack D; Stürenburg E; Seifert H
    J Clin Microbiol; 2007 Apr; 45(4):1167-74. PubMed ID: 17287329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a double synergy differential test (DSDT) for differential detection of ESBL and AmpC-type β-lactamases in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
    Sabia C; Gargiulo R; Sarti M
    New Microbiol; 2012 Apr; 35(2):221-5. PubMed ID: 22707136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.
    Stürenburg E; Lang M; Horstkotte MA; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Nov; 54(5):870-5. PubMed ID: 15471997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 3 phenotypic-detection methods for identifying plasmid-mediated AmpC beta-lactamase-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis strains.
    Lee W; Jung B; Hong SG; Song W; Jeong SH; Lee K; Kwak HS
    Korean J Lab Med; 2009 Oct; 29(5):448-54. PubMed ID: 19893354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of AmpC beta-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory.
    Pitout JD; Le PG; Moore KL; Church DL; Gregson DB
    Clin Microbiol Infect; 2010 Feb; 16(2):165-70. PubMed ID: 19456838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AmpC beta-lactamase producing multidrug resistant strains of Klebsiella spp. & Escherichia coli isolated from children under five in Chennai.
    Subha A; Devi VR; Ananthan S
    Indian J Med Res; 2003 Jan; 117():13-8. PubMed ID: 12866821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis.
    Coudron PE
    J Clin Microbiol; 2005 Aug; 43(8):4163-7. PubMed ID: 16081966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance.
    Hansen DS; Schumacher H; Hansen F; Stegger M; Hertz FB; Schønning K; Justesen US; Frimodt-Møller N;
    Scand J Infect Dis; 2012 Mar; 44(3):174-81. PubMed ID: 22364227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases.
    Colodner R; Reznik B; Gal V; Yamazaki H; Hanaki H; Kubo R
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):49-51. PubMed ID: 16416268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
    Tan TY; Ng SY; Teo L; Koh Y; Teok CH
    J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.